Document Detail

Humanized cobra venom factor: Structure, activity, and therapeutic efficacy in preclinical disease models.
MedLine Citation:
PMID:  25062833     Owner:  NLM     Status:  Publisher    
The complement system is an integral component of both innate and adaptive immunity. However, complement is also a pathogenetic factor in many diseases. The development of agents for therapeutic complement inhibition is the topic of intense investigations by many investigators. We have developed a distinctly different therapeutic approach: complement depletion rather than inhibition. This approach is based on cobra venom factor (CVF), a C3 analog known to be able to safely deplete complement. This manuscript will briefly review the structure and activity of CVF, along with its similarities and differences to C3. Exploiting the knowledge of the structure/function relationship of CVF and C3, we created derivatives of human C3 which display the CVF-like activity of depleting complement, referred to as humanized CVF (hCVF). This review describes the structure and activity of hCVF, including the important property of not cleaving C5. The efficacy of hCVF for therapeutic complement depletion in nine preclinical models diseases with complement pathology is reviewed, including reperfusion injury, age-related macular degeneration (AMD), paroxysmal nocturnal hemoglobinuria (PNH), and immunogenicity of Factor VIII in hemophilia A. Complement depletion is characterized by the absence of toxicity, even after intra-arterial injection into the pulmonary artery of primates. No immunogenicity has been observed.
Carl-Wilhelm Vogel; Paul W Finnegan; David C Fritzinger
Related Documents :
11733573 - Ligand-independent signaling functions for the b lymphocyte antigen receptor and their ...
21191773 - Dendritic cells modifi cation during sublingual immunotherapy in children with allergic...
20361943 - Obaculactone suppresses th1 effector cell function through down-regulation of t-bet and...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2014-7-22
Journal Detail:
Title:  Molecular immunology     Volume:  -     ISSN:  1872-9142     ISO Abbreviation:  Mol. Immunol.     Publication Date:  2014 Jul 
Date Detail:
Created Date:  2014-7-26     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7905289     Medline TA:  Mol Immunol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2014 Elsevier Ltd. All rights reserved.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Structural and antigenic features of the synthetic SF23 peptide corresponding to the receptor bindin...
Next Document:  Airway smooth muscle in asthma: Linking contraction and mechanotransduction to disease pathogenesis ...